When a focal hip cartilage lesion becomes a repair decision

For active adults with a diagnosed focal cartilage lesion of the hip, the immediate question is whether repair — rather than replacement — is still realistic. In most cases where the damage is localised and the wider joint remains structurally sound, it is.

A focal defect is a discrete area of full-thickness cartilage loss — graded ICRS Grade III or IV, typically under 6 cm² — and it differs fundamentally from diffuse hip osteoarthritis, where wear has spread across the joint surface. When imaging confirms a contained lesion with a Tönnis grade below 2, two distinct repair pathways become relevant: the ChondroFiller injection, an outpatient procedure using an injectable collagen scaffold, and AMIC (Autologous Matrix-Induced Chondrogenesis), a single-stage arthroscopic operation. Both sit within the hip preservation tier — above symptom management, below total hip replacement — and both aim to restore the damaged area rather than replace the joint.

The most common presentation is anterosuperior acetabular damage driven by femoroacetabular impingement (FAI). Where impingement is present, it must be corrected alongside any cartilage repair; otherwise the mechanical cause continues to load the repair site. That requirement applies equally to both pathways described in this article.

Patients who reach this decision are typically active adults under 55 seeking to maintain hip function and delay or avoid arthroplasty.

How the two repair mechanisms differ

Despite sharing the same regenerative goal, ChondroFiller injection and AMIC work through opposite mechanical logic — and understanding that difference explains why each suits a different clinical situation.

The ChondroFiller injection is an outpatient procedure delivered under ultrasound guidance in a clinic room, under local anaesthesia. A liquid Type I collagen hydrogel is placed directly into the cartilage defect through a needle, where it self-gels within approximately 3–5 minutes to form a stable matrix inside the void. From that point, the scaffold acts chemotactically — it actively draws the patient's own stem cells and chondrocyte precursors (the precursor cells that produce cartilage matrix) into the defect site. Those recruited cells gradually deposit new cartilage tissue while the collagen framework biodegrades over roughly one to two years. Nothing is removed; the approach is additive and top-down. For the scaffold to function, precise intralesional placement is essential — published orthobiologics data indicate that up to 30% of intra-articular injections performed without imaging guidance fail to land inside the defect itself, dispersing gel into surrounding joint space where the regenerative mechanism cannot proceed.

AMIC follows the opposite sequence. During arthroscopic surgery (keyhole surgery performed under general or spinal anaesthesia), damaged cartilage is first debrided — cleared back to expose clean subchondral bone (the bony layer beneath the cartilage). Small channels are drilled into that bone through a technique called microfracture, releasing bone-marrow stem cells into the defect. A collagen I/III membrane, such as Chondro-Gide, is then fixed over the prepared bed. The membrane stabilises the blood clot that forms from the marrow bleed and channels the released stem cells toward hyaline-like tissue — more structurally durable than the fibrocartilage that microfracture alone tends to produce. Reconstruction proceeds from the bone upward.

Both pathways rely entirely on the patient's own biology to generate new tissue; neither inserts synthetic or donor cartilage.

Which patients suit each pathway

Eligibility for each pathway turns on three intersecting factors: defect size, overall joint condition, and surgical fitness.

ChondroFiller injection candidates

The ChondroFiller injection is designed for patients with a focal ICRS Grade III or IV defect — structurally significant damage, but contained — typically up to approximately 6 cm² in area, with the subchondral bone plate intact beneath it. The surrounding joint must show minimal arthritic change (Tönnis grade below 2). Because the procedure requires no general anaesthesia, theatre admission, or incision, it is also appropriate for patients who are medically unsuitable for surgery, or who prefer a non-surgical route given an otherwise suitable lesion profile.

AMIC candidates

AMIC is generally reserved for larger focal defects — often 2 cm² or more — where structural reconstruction from the bone bed upward is clinically warranted. The procedure requires arthroscopic surgery under general or spinal anaesthesia, and the strongest published evidence (the 2024 Bone & Joint mid-term study, mean patient age 26.8 years) comes from younger, surgically fit adults. AMIC is frequently performed alongside FAI osteoplasty at the same operative sitting to remove the mechanical cause of cartilage damage.

The overlap zone and shared contraindications

For defects in the 2–4 cm² range, both pathways may be technically feasible. The deciding factors are surgical fitness, patient preference, and whether the subchondral bone plate remains sufficiently intact to support an additive approach.

Neither procedure is appropriate where established osteoarthritis is present (Tönnis grade 2 or above), where wear is diffuse rather than focal, where inflammatory arthropathy affects the joint, or where significant malalignment cannot be corrected simultaneously.

A consultant assessment — including MRI characterisation of the lesion and full joint evaluation — is needed to determine which pathway, if either, is suitable. Lincolnshire Hip accepts patients without GP referral for this type of hip preservation assessment.

What the clinical evidence shows

The evidence for both pathways is promising at mid-term, but drawn from small cohorts without direct comparison — a limitation both techniques share at this stage of development.

Clinical cohort data for ChondroFiller injection report 70–85% symptom relief sustained over three to five years. An expert comparative analysis of published cartilage-repair data places ChondroFiller's IKDC functional improvement at approximately 30 points, with a complication rate of approximately 0% and a reoperation rate of 3–8% — favourably positioned against microfracture (reoperation rates up to 41%) and ACI/MACI (complications up to 17%, reoperation rates up to 37%). These figures are drawn from multi-joint cohorts rather than hip-specific randomised trials, and long-term hip-only outcome data remain limited.

For AMIC in the hip, the strongest available dataset is the 2024 Bone & Joint Journal mid-term study: 12 hips, mean age 26.8 years, all lesions ≥2 cm², mean follow-up 6.2 years. MOCART score reached 66.3, Oxford Hip Score improved from 37.4 to 42.7 (p=0.014), and COMI score fell from 4.1 to 1.6 (p=0.025); no patient required conversion to total hip arthroplasty. The AMIC Registry (Gille et al., 57 patients, mean defect 3.4 cm²) confirms significant VAS pain reduction at one and two years post-operatively (p<0.001), with MRI demonstrating tissue infilling in most cases. A 2025 systematic review by Mahatme et al. describes AMIC as an encouraging option for focal hip lesions managed arthroscopically.

No head-to-head randomised trial comparing ChondroFiller injection to AMIC in the hip currently exists — not unusual for techniques at this stage. The two datasets reflect different patient populations, defect sizes, and follow-up periods, which is why individual assessment with MRI review, rather than published averages, forms the basis for any treatment recommendation.

The patient journey: outpatient injection vs hip arthroscopy

The ChondroFiller injection takes place in a clinic room — no theatre booking, no general anaesthesia, no overnight stay. At Lincolnshire Hip's Sleaford and Grantham sites, the gel is placed under ultrasound or fluoroscopic guidance in a single session of around 30–60 minutes; patients leave the same day and can bear weight immediately. Recovery is measured in days to weeks rather than months.

AMIC requires an operating theatre and general or spinal anaesthesia, often at the same sitting as FAI correction. Mandatory non-weight-bearing follows surgery — typically several weeks on crutches — before a structured physiotherapy programme begins. Return to strenuous activity and sport is measured in months. This is not a reason to dismiss the surgical route; patients who are younger, surgically fit, and carrying lesions of 2 cm² or more may be well placed for it. The point is that the two pathways ask very different things of the patient's body and diary.

On access and cost: the ChondroFiller injection is available on a self-funded basis at approximately £3,000–£8,000, and is not NHS-funded nor covered by major UK private insurers including Bupa or AXA. AMIC may be accessible via NHS referral at appropriate surgical centres, depending on the clinical pathway agreed with the referring team.

Both pathways include physiotherapy, though AMIC's rehabilitation programme is considerably longer and more intensive. For patients who cannot safely undergo general anaesthesia, or who prefer to avoid theatre admission for a lesion that meets the ChondroFiller injection criteria, the outpatient route removes those barriers entirely.

Choosing between the two pathways

The two pathways address different clinical problems. Defect size offers the sharpest selection signal: focal lesions typically under 2 cm², in patients who prefer or require a non-surgical route, tend to suit the ChondroFiller injection; lesions of 2 cm² or more, in surgically fit younger adults who can complete a structured rehabilitation programme, are more likely candidates for AMIC. That size threshold is a guide, not a rule — lesion grade, subchondral bone integrity, the presence of FAI, and recovery capacity all sit alongside it in the decision.

On FAI specifically: where impingement is driving the cartilage damage, addressing it is not optional. Neither technique can sustain a repair at a site that continues to be mechanically loaded by an uncorrected cam or pincer deformity — and that consideration applies regardless of which pathway is chosen.

No trial has yet compared these two approaches directly in the hip. The available datasets cover different patient ages, defect sizes, and follow-up durations, which is the honest reason individual assessment with current MRI carries more weight than any published average. For patients considering either pathway, both options can be evaluated at a single appointment alongside imaging review; Lincolnshire Hip, part of the MSK Doctors group, accepts patients without referral for hip assessment at its Sleaford and Grantham sites.